As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > COLUMN
COLUMN
- Current Topics of New Drug Development and Marketing in the World: 2
July 10, 2015
- Current Topics of New Drug Development and Marketing in the World: 1
July 9, 2015
- The Mastery of Recruitment
June 26, 2015
- “Every Search Is Won Before It’s Ever Fought”: Sun Tzu
May 22, 2015
- The Truth about Recruiters
April 21, 2015
- When Interviewing, Share the Love
March 27, 2015
- Sales Experience for Marketers Deceasing in Japan’s Pharma Industry
February 20, 2015
- Eliminating Bias from the Interview Process
January 23, 2015
- Loss Aversion: Why Candidates Reject Offers
December 26, 2014
- What You Don’t Know About Communication Can Hurt You
November 28, 2014
- 3 Reasons Why KOL Management Is No Longer Enough
October 22, 2014
- Successful People Have the Best Information
September 24, 2014
- Is Your Body Language Louder than Your Speech?
August 25, 2014
- Taking Pride in Small Things Makes Big Things Possible
July 25, 2014
- It’s Moments Like These
June 27, 2014
- How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
- Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
- Emerging Immunotherapy of Cancer: 2
April 11, 2014
- Emerging Immunotherapy of Cancer: 1
April 10, 2014
- Sun Tzu and the Art of Interviewing
March 18, 2014
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…